AGEN
Agenus Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.34
+1.15%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.5x
Market Cap
$375.25M
MomentumView details →
1D Return
+1.15%
YTD Return
+162.10%
RSI (14)
60.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.5x
Market Cap
$375.25M
RSI (14)
60.6
MomentumView details →
1D Return
+1.15%
YTD Return
+162.10%
SummaryUpdated Jun 1, 2026
Agenus Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology biotechnology company founded in 1994 and headquartered in Lexington, Massachusetts. Originally incorporated as Antigenics Inc., the company changed its name to Agenus in January 2011. Agenus focuses on discovering and developing innovative cancer immunotherapies, with its lead program being the combination therapy of botensilimab and balstilimab (BOT/BAL) showing promising results in treating various solid tumors, particularly colorectal cancer. The company went public in February 2000 and has built a comprehensive pipeline of immuno-oncology treatments while also developing proprietary antibody discovery platforms.
Similar companies
Latest newsMore news →
Agenus announced the peer-reviewed publication of updated results from the Phase 2 NEST trial of neoadjuvant botensilimab and balstilimab in resectable colon cancer, reporting deep pathologic responses and no observed recurrences.9d agoAgenus Inc. amended and restated its existing promissory note with Ocean 1181 LLC, extending the maturity to November 30, 2029, maintaining a 13.0% annual interest rate, and adding a $247,500 extension fee, half of which is payable in common stock.18d agoAgenus Inc. advanced its Phase 3 ROBBIN trial of botensilimab plus balstilimab in neoadjuvant MSS colon cancer.29d ago